with immune-mediated inflammation, itch, and bacterial components of the disease simultaneously as part of a singular treatment approach. The company supports its pipeline of dermatologic therapeutics with multiple bioactive compounds intended to engage several mechanisms of action within skin disease pathology. Alphyn maintains an intellectual property portfolio that spans its platform and product candidates. Zabalafin Hydrogel has progressed through Phase 2 clinical evaluation with ongoing Phase 2b studies and associated research publications.